CB06 / Zhimeng Biopharma - LARVOL DELTA

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Shanghai Zhimeng Biopharma, Inc. | Recruiting ➔ Completed | Phase classification: P1/2 ➔ P1 | Trial completion date: Dec 2025 ➔ Feb 2025

Phase classification • Trial completion • Trial completion date • Hepatitis B • Infectious Disease • Inflammation • CCL11 • CXCL8 • IL1R1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Shanghai Zhimeng Biopharma, Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2024 ➔ Dec 2025 | Trial primary completion date: Mar 2024 ➔ Dec 2024

Enrollment open • Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Shanghai Zhimeng Biopharma, Inc.

New P1 trial